|Articles|February 4, 1998

FDA approves Bracco’s LumenHance

Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has

Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has licensed the agent from its developer, ImaRx Pharmaceutical of Tucson.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Latest CME